Trobalt

RSS

retigabine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Trobalt has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 19/11/2018

Authorisation details

Product details
Name
Trobalt
Agency product number
EMEA/H/C/001245
Active substance
retigabine
International non-proprietary name (INN) or common name
retigabine
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX21
Publication details
Marketing-authorisation holder
Glaxo Group Limited 
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
27/03/2011
Contact address
Glaxo Group Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

Product information

19/07/2018 Trobalt - EMEA/H/C/001245 - IAIN/0043

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti epileptics

Therapeutic indication

Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

Assessment history

How useful was this page?

Add your rating
Average
1 rating